Browsing ODA Open Digital Archive by Author "Buer, Lydia Celine Tansem"

Now showing items 1-2 of 2

Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study

Helm, Thea Elisabeth; Høivik, Marte Lie; Anisdahl, Karoline; Buer, Lydia Celine Tansem; Warren, David; Bolstad, Nils; Småstuen, Milada Cvancarova; Moum, Bjørn Allan; Medhus, Asle Wilhelm (Peer reviewed; Journal article, 2024)

Background: Vedolizumab has since 2021 been available as a subcutaneous formulation. We aimed to assess 18-month drug persistence and possible predictive factors associated with discontinuation, safety, serum drug profile, ...
Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring

Wiken, Thea H.; Høivik, Marte Lie; Buer, Lydia Celine Tansem; Warren, David J.; Bolstad, Nils; Moum, Bjørn Allan; Anisdahl, Karoline; Småstuen, Milada Cvancarova; Medhus, Asle Wilhelm (Peer reviewed; Journal article, 2023)

Objective: Vedolizumab (VDZ) for subcutaneous (SC) administration has recently become available. We aimed to assess feasibility, safety and clinical outcome when switching from intravenous (IV) to SC VDZ maintenance ...